Clinical usefulness of newly developed prognostic predictive score for atezolizumab plus bevacizumab for hepatocellular carcinoma

Hideko Ohama; Atsushi Hiraoka; Toshifumi Tada; Masashi Hirooka; Kazuya Kariyama; Takeshi Hatanaka; Joji Tani; Koichi Takaguchi; Masanori Atsukawa; Ei Itobayashi; Takashi Nishimura; Kunihiko Tsuji; Kazuto Tajiri; Toru Ishikawa; Satoshi Yasuda; Hidenori Toyoda; Shinya Fukunishi; Chikara Ogawa; Satoru Kakizaki; Noritomo Shimada; Atsushi Naganuma; Kazuhito Kawata; Hisashi Kosaka; Hidekatsu Kuroda; Tomomitsu Matono; Yutaka Yata; Hironori Ochi; Fujimasa Tada; Kazuhiro Nouso; Asahiro Morishita; Norio Itokawa; Tomomi Okubo; Taeang Arai; Akemi Tsutsui; Takuya Nagano; Keisuke Yokohama; Hiroki Nishikawa; Michitaka Imai; Yohei Koizumi; Shinichiro Nakamura; Hiroko Iijima; Masaki Kaibori; Yoichi Hiasa; Takashi Kumada

doi:10.1002/cnr2.2042

Clinical usefulness of newly developed prognostic predictive score for atezolizumab plus bevacizumab for hepatocellular carcinoma

Hideko Ohama, Atsushi Hiraoka^*, Toshifumi Tada, Masashi Hirooka, Kazuya Kariyama, Takeshi Hatanaka, Joji Tani, Koichi Takaguchi, Masanori Atsukawa, Ei Itobayashi, Takashi Nishimura, Kunihiko Tsuji, Kazuto Tajiri, Toru Ishikawa, Satoshi Yasuda, Hidenori Toyoda, Shinya Fukunishi, Chikara Ogawa, Satoru Kakizaki, Noritomo ShimadaAtsushi Naganuma, Kazuhito Kawata, Hisashi Kosaka, Hidekatsu Kuroda, Tomomitsu Matono, Yutaka Yata, Hironori Ochi, Fujimasa Tada, Kazuhiro Nouso, Asahiro Morishita, Norio Itokawa, Tomomi Okubo, Taeang Arai, Akemi Tsutsui, Takuya Nagano, Keisuke Yokohama, Hiroki Nishikawa, Michitaka Imai, Yohei Koizumi, Shinichiro Nakamura, Hiroko Iijima, Masaki Kaibori, Yoichi Hiasa, Takashi Kumada

^*Corresponding author for this work

Internal Medicine （3）

Research output: Contribution to journal › Article › peer-review

4 Scopus citations

Abstract

Aims: The aim of the present study was to elucidate detailed parameters for prediction of prognosis for patients with unresectable hepatocellular carcinoma (uHCC) receiving atezolizumab plus bevacizumab (Atez/Bev) treatment. Methods: A total of 719 patients (males 577, median age 74 years) treated with Atez/Bev between September 2020 and January 2023 were enrolled. Factors related to overall survival (OS) were extracted and a prognostic scoring system based on hazard ratio (HR) was created. OS and progression-free survival (PFS) were retrospectively examined, and the prognostic ability of the newly developed system was compared to CRAFITY score using concordance index (c-index) and Akaike information criterion (AIC) results. Results: Cox-hazards multivariate analysis showed BCLC classification C/D (HR 1.4; 1 point), AFP ≥100 ng/mL (HR 1.4; 1 point), mALBI 2a (HR 1.7; 1 point), mALBI 2b/3 (HR 2.8; 2 points), and DCP ≥100 mAU/mL (HR 1.6; 1 point) as significant factors. The assigned points were added and used to develop the IMmunotherapy with AFP, BCLC staging, mALBI, and DCP evaluation (IMABALI-De) scoring system. For IMABALI-De scores of 0, 1, 2, 3, 4, and 5, OS was not applicable (NA), NA, 26.11, 18.79, 14.07, and 8.32 months, respectively (p <.001; AIC 2788.67, c-index 0.699), while for CRAFITY scores of 0, 1, and 2, OS was 26.11, 20.29, and 11.32 months, respectively (p <.001; AIC 2864.54, c-index 0.606). PFS periods for those IMABALI-De scores were 21.75, 12.89, 9.18, 8.0, 5.0, and 3.75 months, respectively (p <.001; AIC 5203.32, c-index 0.623) and for the CRAFITY scores were 10.32, 7.68, and 3.57 months, respectively (p <.001; AIC 5246.61, c-index 0.574). As compared with CRAFITY score, IMABALI-De score had better AIC and c-index results for both OS and PFS. Conclusion: The present results indicated that the proposed IMABALI-De score may be favorable for predicting prognosis of uHCC patients receiving Atez/Bev therapy.

Original language	English
Article number	e2042
Journal	Cancer Reports
Volume	7
Issue number	4
DOIs	https://doi.org/10.1002/cnr2.2042
State	Published - 2024/04

Keywords

CRAFITY score
IMABALI score
IMABALI-De score
atezolizumab plus bevacizumab
hepatocellular carcinoma
modified albumin-bilirubin grade
prognosis

ASJC Scopus subject areas

Oncology
Cancer Research

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1002/cnr2.2042

Cite this

Ohama, H., Hiraoka, A., Tada, T., Hirooka, M., Kariyama, K., Hatanaka, T., Tani, J., Takaguchi, K., Atsukawa, M., Itobayashi, E., Nishimura, T., Tsuji, K., Tajiri, K., Ishikawa, T., Yasuda, S., Toyoda, H., Fukunishi, S., Ogawa, C., Kakizaki, S., ... Kumada, T. (2024). Clinical usefulness of newly developed prognostic predictive score for atezolizumab plus bevacizumab for hepatocellular carcinoma. Cancer Reports, 7(4), Article e2042. https://doi.org/10.1002/cnr2.2042

@article{568ae86103f144199ed7e72bafd9617c,

title = "Clinical usefulness of newly developed prognostic predictive score for atezolizumab plus bevacizumab for hepatocellular carcinoma",

abstract = "Aims: The aim of the present study was to elucidate detailed parameters for prediction of prognosis for patients with unresectable hepatocellular carcinoma (uHCC) receiving atezolizumab plus bevacizumab (Atez/Bev) treatment. Methods: A total of 719 patients (males 577, median age 74 years) treated with Atez/Bev between September 2020 and January 2023 were enrolled. Factors related to overall survival (OS) were extracted and a prognostic scoring system based on hazard ratio (HR) was created. OS and progression-free survival (PFS) were retrospectively examined, and the prognostic ability of the newly developed system was compared to CRAFITY score using concordance index (c-index) and Akaike information criterion (AIC) results. Results: Cox-hazards multivariate analysis showed BCLC classification C/D (HR 1.4; 1 point), AFP ≥100 ng/mL (HR 1.4; 1 point), mALBI 2a (HR 1.7; 1 point), mALBI 2b/3 (HR 2.8; 2 points), and DCP ≥100 mAU/mL (HR 1.6; 1 point) as significant factors. The assigned points were added and used to develop the IMmunotherapy with AFP, BCLC staging, mALBI, and DCP evaluation (IMABALI-De) scoring system. For IMABALI-De scores of 0, 1, 2, 3, 4, and 5, OS was not applicable (NA), NA, 26.11, 18.79, 14.07, and 8.32 months, respectively (p <.001; AIC 2788.67, c-index 0.699), while for CRAFITY scores of 0, 1, and 2, OS was 26.11, 20.29, and 11.32 months, respectively (p <.001; AIC 2864.54, c-index 0.606). PFS periods for those IMABALI-De scores were 21.75, 12.89, 9.18, 8.0, 5.0, and 3.75 months, respectively (p <.001; AIC 5203.32, c-index 0.623) and for the CRAFITY scores were 10.32, 7.68, and 3.57 months, respectively (p <.001; AIC 5246.61, c-index 0.574). As compared with CRAFITY score, IMABALI-De score had better AIC and c-index results for both OS and PFS. Conclusion: The present results indicated that the proposed IMABALI-De score may be favorable for predicting prognosis of uHCC patients receiving Atez/Bev therapy.",

keywords = "CRAFITY score, IMABALI score, IMABALI-De score, atezolizumab plus bevacizumab, hepatocellular carcinoma, modified albumin-bilirubin grade, prognosis",

author = "Hideko Ohama and Atsushi Hiraoka and Toshifumi Tada and Masashi Hirooka and Kazuya Kariyama and Takeshi Hatanaka and Joji Tani and Koichi Takaguchi and Masanori Atsukawa and Ei Itobayashi and Takashi Nishimura and Kunihiko Tsuji and Kazuto Tajiri and Toru Ishikawa and Satoshi Yasuda and Hidenori Toyoda and Shinya Fukunishi and Chikara Ogawa and Satoru Kakizaki and Noritomo Shimada and Atsushi Naganuma and Kazuhito Kawata and Hisashi Kosaka and Hidekatsu Kuroda and Tomomitsu Matono and Yutaka Yata and Hironori Ochi and Fujimasa Tada and Kazuhiro Nouso and Asahiro Morishita and Norio Itokawa and Tomomi Okubo and Taeang Arai and Akemi Tsutsui and Takuya Nagano and Keisuke Yokohama and Hiroki Nishikawa and Michitaka Imai and Yohei Koizumi and Shinichiro Nakamura and Hiroko Iijima and Masaki Kaibori and Yoichi Hiasa and Takashi Kumada",

note = "Publisher Copyright: {\textcopyright} 2024 The Authors. Cancer Reports published by Wiley Periodicals LLC.",

year = "2024",

month = apr,

doi = "10.1002/cnr2.2042",

language = "英語",

volume = "7",

journal = "Cancer Reports",

issn = "2573-8348",

publisher = "Wiley-Blackwell Publishing Ltd",

number = "4",

}

Ohama, H, Hiraoka, A, Tada, T, Hirooka, M, Kariyama, K, Hatanaka, T, Tani, J, Takaguchi, K, Atsukawa, M, Itobayashi, E, Nishimura, T, Tsuji, K, Tajiri, K, Ishikawa, T, Yasuda, S, Toyoda, H, Fukunishi, S, Ogawa, C, Kakizaki, S, Shimada, N, Naganuma, A, Kawata, K, Kosaka, H, Kuroda, H, Matono, T, Yata, Y, Ochi, H, Tada, F, Nouso, K, Morishita, A, Itokawa, N, Okubo, T, Arai, T, Tsutsui, A, Nagano, T, Yokohama, K, Nishikawa, H, Imai, M, Koizumi, Y, Nakamura, S, Iijima, H, Kaibori, M, Hiasa, Y & Kumada, T 2024, 'Clinical usefulness of newly developed prognostic predictive score for atezolizumab plus bevacizumab for hepatocellular carcinoma', Cancer Reports, vol. 7, no. 4, e2042. https://doi.org/10.1002/cnr2.2042

TY - JOUR

T1 - Clinical usefulness of newly developed prognostic predictive score for atezolizumab plus bevacizumab for hepatocellular carcinoma

AU - Ohama, Hideko

AU - Hiraoka, Atsushi

AU - Tada, Toshifumi

AU - Hirooka, Masashi

AU - Kariyama, Kazuya

AU - Hatanaka, Takeshi

AU - Tani, Joji

AU - Takaguchi, Koichi

AU - Atsukawa, Masanori

AU - Itobayashi, Ei

AU - Nishimura, Takashi

AU - Tsuji, Kunihiko

AU - Tajiri, Kazuto

AU - Ishikawa, Toru

AU - Yasuda, Satoshi

AU - Toyoda, Hidenori

AU - Fukunishi, Shinya

AU - Ogawa, Chikara

AU - Kakizaki, Satoru

AU - Shimada, Noritomo

AU - Naganuma, Atsushi

AU - Kawata, Kazuhito

AU - Kosaka, Hisashi

AU - Kuroda, Hidekatsu

AU - Matono, Tomomitsu

AU - Yata, Yutaka

AU - Ochi, Hironori

AU - Tada, Fujimasa

AU - Nouso, Kazuhiro

AU - Morishita, Asahiro

AU - Itokawa, Norio

AU - Okubo, Tomomi

AU - Arai, Taeang

AU - Tsutsui, Akemi

AU - Nagano, Takuya

AU - Yokohama, Keisuke

AU - Nishikawa, Hiroki

AU - Imai, Michitaka

AU - Koizumi, Yohei

AU - Nakamura, Shinichiro

AU - Iijima, Hiroko

AU - Kaibori, Masaki

AU - Hiasa, Yoichi

AU - Kumada, Takashi

PY - 2024/4

Y1 - 2024/4

N2 - Aims: The aim of the present study was to elucidate detailed parameters for prediction of prognosis for patients with unresectable hepatocellular carcinoma (uHCC) receiving atezolizumab plus bevacizumab (Atez/Bev) treatment. Methods: A total of 719 patients (males 577, median age 74 years) treated with Atez/Bev between September 2020 and January 2023 were enrolled. Factors related to overall survival (OS) were extracted and a prognostic scoring system based on hazard ratio (HR) was created. OS and progression-free survival (PFS) were retrospectively examined, and the prognostic ability of the newly developed system was compared to CRAFITY score using concordance index (c-index) and Akaike information criterion (AIC) results. Results: Cox-hazards multivariate analysis showed BCLC classification C/D (HR 1.4; 1 point), AFP ≥100 ng/mL (HR 1.4; 1 point), mALBI 2a (HR 1.7; 1 point), mALBI 2b/3 (HR 2.8; 2 points), and DCP ≥100 mAU/mL (HR 1.6; 1 point) as significant factors. The assigned points were added and used to develop the IMmunotherapy with AFP, BCLC staging, mALBI, and DCP evaluation (IMABALI-De) scoring system. For IMABALI-De scores of 0, 1, 2, 3, 4, and 5, OS was not applicable (NA), NA, 26.11, 18.79, 14.07, and 8.32 months, respectively (p <.001; AIC 2788.67, c-index 0.699), while for CRAFITY scores of 0, 1, and 2, OS was 26.11, 20.29, and 11.32 months, respectively (p <.001; AIC 2864.54, c-index 0.606). PFS periods for those IMABALI-De scores were 21.75, 12.89, 9.18, 8.0, 5.0, and 3.75 months, respectively (p <.001; AIC 5203.32, c-index 0.623) and for the CRAFITY scores were 10.32, 7.68, and 3.57 months, respectively (p <.001; AIC 5246.61, c-index 0.574). As compared with CRAFITY score, IMABALI-De score had better AIC and c-index results for both OS and PFS. Conclusion: The present results indicated that the proposed IMABALI-De score may be favorable for predicting prognosis of uHCC patients receiving Atez/Bev therapy.

AB - Aims: The aim of the present study was to elucidate detailed parameters for prediction of prognosis for patients with unresectable hepatocellular carcinoma (uHCC) receiving atezolizumab plus bevacizumab (Atez/Bev) treatment. Methods: A total of 719 patients (males 577, median age 74 years) treated with Atez/Bev between September 2020 and January 2023 were enrolled. Factors related to overall survival (OS) were extracted and a prognostic scoring system based on hazard ratio (HR) was created. OS and progression-free survival (PFS) were retrospectively examined, and the prognostic ability of the newly developed system was compared to CRAFITY score using concordance index (c-index) and Akaike information criterion (AIC) results. Results: Cox-hazards multivariate analysis showed BCLC classification C/D (HR 1.4; 1 point), AFP ≥100 ng/mL (HR 1.4; 1 point), mALBI 2a (HR 1.7; 1 point), mALBI 2b/3 (HR 2.8; 2 points), and DCP ≥100 mAU/mL (HR 1.6; 1 point) as significant factors. The assigned points were added and used to develop the IMmunotherapy with AFP, BCLC staging, mALBI, and DCP evaluation (IMABALI-De) scoring system. For IMABALI-De scores of 0, 1, 2, 3, 4, and 5, OS was not applicable (NA), NA, 26.11, 18.79, 14.07, and 8.32 months, respectively (p <.001; AIC 2788.67, c-index 0.699), while for CRAFITY scores of 0, 1, and 2, OS was 26.11, 20.29, and 11.32 months, respectively (p <.001; AIC 2864.54, c-index 0.606). PFS periods for those IMABALI-De scores were 21.75, 12.89, 9.18, 8.0, 5.0, and 3.75 months, respectively (p <.001; AIC 5203.32, c-index 0.623) and for the CRAFITY scores were 10.32, 7.68, and 3.57 months, respectively (p <.001; AIC 5246.61, c-index 0.574). As compared with CRAFITY score, IMABALI-De score had better AIC and c-index results for both OS and PFS. Conclusion: The present results indicated that the proposed IMABALI-De score may be favorable for predicting prognosis of uHCC patients receiving Atez/Bev therapy.

KW - CRAFITY score

KW - IMABALI score

KW - IMABALI-De score

KW - atezolizumab plus bevacizumab

KW - hepatocellular carcinoma

KW - modified albumin-bilirubin grade

KW - prognosis

UR - http://www.scopus.com/inward/record.url?scp=85189613475&partnerID=8YFLogxK

U2 - 10.1002/cnr2.2042

DO - 10.1002/cnr2.2042

M3 - 学術論文

C2 - 38577725

AN - SCOPUS:85189613475

SN - 2573-8348

VL - 7

JO - Cancer Reports

JF - Cancer Reports

IS - 4

M1 - e2042

ER -

Clinical usefulness of newly developed prognostic predictive score for atezolizumab plus bevacizumab for hepatocellular carcinoma

Abstract

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Fingerprint

Cite this